Clinsights: Making Information A Competitive Advantage
Executive Summary
Clinsights uses advanced information systems technology to aggregate population-based clinical outcomes data, and to disseminate this data to device companies and physicians. The company's data collection services include e-registries for clinical research, outcomes databases at key clinical centers, and post-market surveillance studies, and the information is disseminated through specialty websites and Internet-based data systems.Key to Clinsights' approach is building relationships with thought leaders in different clinical specialties, the first of which is interventional cardiology. In this area, Clinsights is working with the Cardiovascular Research Foundation (CRF), sponsors of the leading interventional cardiology conference, the Transcatheter Cardiovascular Therapeutics (TCT) meeting. This partnership has produced Clinsights' first website, TCTMD.com.Clinsights' bet is that it can convince medical device companies of the value of its services, built around the ability to collect and disseminate information, and enhanced by partnerships with leading physicians, in providing a competitive advantage that can help differentiate products and technologies.
You may also be interested in...
Clinical Trials: Eliminating the Paper Chase
For years, companies have offered remote data entry systems to transfer data from trial sites to a central server. But Big Pharma has by and large stuck to its old-fashioned paper ways. Now several start-ups are offering a new breed of web-based RDE and the pharmaceutical industry is starting to take interest. But before embracing an online approach to data collection, drug companies want proof that doing so will save them time and money. Pharma companies must also evaluate how to integrate data collection and management into the rest of their infrastructures. Collaboration rather than competition might best enable pharmaceutical; companies to fully realize the benefits of web-enabled trials through the cooperative sharing of resources.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.